All In Biotech

Free tool

FAERS Monitor: Osphena

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203505 or its brand name (Osphena, Ospemifene). Reports on generic versions are filed under their own applications.

Reports

2,605

Serious

481

18% of reports

Hospitalization

120

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use452
  • hot flush372
  • headache209
  • muscle spasms194
  • no adverse event173
  • vaginal haemorrhage150
  • vaginal discharge134
  • labelled drug-drug interaction medication error111
  • nausea108
  • hyperhidrosis107
  • drug ineffective94
  • rash88
  • fatigue86
  • pain in extremity78
  • therapeutic response unexpected75

Reports by year received

View as table
YearReports
201393
2014491
2015446
2016589
2017285
2018419
2019108
202049
202137
202219
202321
202417
202517
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,554 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vaginal dischargeSignal134108.391.713,959
labelled drug-drug interaction medication errorSignal111102.685.510,937
hot flushSignal37240.036.414,104
vaginal haemorrhageSignal15028.024.03,872
therapeutic response unexpectedSignal7513.510.8857
muscle spasmsSignal1948.57.51,294
no adverse eventSignal1737.76.71,012
hyperhidrosisSignal1076.75.6517
off label useSignal4524.23.81,132
headacheSignal2092.72.4227
pain in extremitySignal782.11.747
rash881.61.321
nausea1081.10.91
fatigue860.90.71
drug ineffective940.60.531

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.